drugset / Trial / NCT03991000

Iron in Patients With Cardiovascular Disease

NCT03991000

Phase 3 Terminated 8 enrolled Dr. med. Mahir Karakas
RandomizedParallel-groupQuadruple-blindTreatment

Summary

It is now recognized that iron deficiency in cardiovascular disease contributes to impaired clinical outcome.

Timeline

Start
2019-02-28
Primary completion
2021-12-15
Completion
2021-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 500 mg Intravenous